Home » Cancer Tubulin Inhibitors Market
Cancer Tubulin Inhibitors Market
Published date: Aug 2022 •Formats:
Request Sample Schedule a Call

Global Cancer Tubulin Inhibitors Market By Type (Docetaxel, Trastuzumab Emtansine, Abraxane, Brentuximab Vedotin, and Cabazitaxel), By Application (Non Small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Colorectal Cancer, and Ovarian Cancer), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2019-2028

  • Published date: Aug 2022
  • Report ID: 39241
  • Number of Pages: 379
  • Format:
  • keyboard_arrow_up
    • 1. Cancer Tubulin Inhibitors Market Introduction
      • 1.1. Definition
      • 1.2. Taxonomy
      • 1.3. Research Scope
    • 2. Executive Summary
      • 2.1. Key Findings by Major Segments
      • 2.2. Top strategies by Major Players
    • 3. Global Cancer Tubulin Inhibitors Market Overview
      • 3.1. Cancer Tubulin Inhibitors Market Dynamics
        • 3.1.1. Drivers
        • 3.1.2. Opportunities
        • 3.1.3. Restraints
        • 3.1.4. Challenges
      • 3.2. PESTLE Analysis
      • 3.3. Opportunity Map Analysis
      • 3.4. PORTER'S Five Forces Analysis
      • 3.5. Market Competition Scenario Analysis
      • 3.6. Product Life Cycle Analysis
      • 3.7. Opportunity Orbits
      • 3.8. Production Analysis by Region/Company
      • 3.9. Industry chain Analysis
      • 3.10. Marketing Strategy
    • 4. Global Cancer Tubulin Inhibitors Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
      • 4.1. Global Cancer Tubulin Inhibitors Market Analysis by Type: Introduction
      • 4.2. Market Size and Forecast by Region
      • 4.3. Docetaxel
      • 4.4. Trastuzumab Emtansine
      • 4.5. Abraxane
      • 4.6. Brentuximab Vedotin
      • 4.7. Cabazitaxel
    • 5. Global Cancer Tubulin Inhibitors Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
      • 5.1. Global Cancer Tubulin Inhibitors Market Analysis by Application: Introduction
      • 5.2. Market Size and Forecast by Region
      • 5.3. Non Small Cell Lung Cancer
      • 5.4. Prostate Cancer
      • 5.5. Breast Cancer
      • 5.6. Colorectal Cancer
      • 5.7. Ovarian Cancer
    • 6. Global Cancer Tubulin Inhibitors Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
      • 6.1. North America
        • 6.1.1. North America Cancer Tubulin Inhibitors Market: Regional Trend Analysis
          • 6.1.1.1. US
          • 6.1.1.2. Canada
          • 6.1.1.3. Mexico
      • 6.2.1. Europe
        • 6.2.1. Europe Cancer Tubulin Inhibitors Market: Regional Trend Analysis
          • 6.2.1.1. Germany
          • 6.2.1.2. France
          • 6.2.1.3. UK
          • 6.2.1.4. Russia
          • 6.2.1.5. Italy
          • 6.2.1.6. Spain
          • 6.2.1.7. Rest of Europe
      • 6.3. Asia-Pacific
        • 6.3.1. Asia-Pacific Cancer Tubulin Inhibitors Market: Regional Trend Analysis
          • 6.3.1.1. China
          • 6.3.1.2. Japan
          • 6.3.1.3. Korea
          • 6.3.1.4. India
          • 6.3.1.5. Rest of Asia-Pacific
      • 6.4. Latin America
        • 6.4.1. Latin America Cancer Tubulin Inhibitors Market: Regional Trend Analysis
          • 6.4.1.1. Brazil
          • 6.4.1.2. Argentina
          • 6.4.1.3. Rest of Latin America
      • 6.5. Middle East and Africa
        • 6.5.1. Middle East and Africa Cancer Tubulin Inhibitors Market: Regional Trend Analysis
          • 6.5.1.1. GCC
          • 6.5.1.2. South Africa
          • 6.5.1.3. Israel
          • 6.5.1.4. Rest of MEA
    • 7. Global Cancer Tubulin Inhibitors Market Competitive Landscape, Market Share Analysis, and Company Profiles
      • 7.1. Market Share Analysis
      • 7.2. Company Profiles
      • 7.3. Abraxis Biosciences
        • 7.3.1. Company Overview
        • 7.3.2. Financial Highlights
        • 7.3.3. Product Portfolio
        • 7.3.4. SWOT Analysis
        • 7.3.5. Key Strategies and Developments
      • 7.4. Agensys
        • 7.4.1. Company Overview
        • 7.4.2. Financial Highlights
        • 7.4.3. Product Portfolio
        • 7.4.4. SWOT Analysis
        • 7.4.5. Key Strategies and Developments
      • 7.5. Amgen
        • 7.5.1. Company Overview
        • 7.5.2. Financial Highlights
        • 7.5.3. Product Portfolio
        • 7.5.4. SWOT Analysis
        • 7.5.5. Key Strategies and Developments
      • 7.6. Celgene
        • 7.6.1. Company Overview
        • 7.6.2. Financial Highlights
        • 7.6.3. Product Portfolio
        • 7.6.4. SWOT Analysis
        • 7.6.5. Key Strategies and Developments
      • 7.7. Eagle Pharmaceuticals
        • 7.7.1. Company Overview
        • 7.7.2. Financial Highlights
        • 7.7.3. Product Portfolio
        • 7.7.4. SWOT Analysis
        • 7.7.5. Key Strategies and Developments
      • 7.8. Endocyte
        • 7.8.1. Company Overview
        • 7.8.2. Financial Highlights
        • 7.8.3. Product Portfolio
        • 7.8.4. SWOT Analysis
        • 7.8.5. Key Strategies and Developments
      • 7.9. Genentech
        • 7.9.1. Company Overview
        • 7.9.2. Financial Highlights
        • 7.9.3. Product Portfolio
        • 7.9.4. SWOT Analysis
        • 7.9.5. Key Strategies and Developments
      • 7.10. Immunogen
        • 7.10.1. Company Overview
        • 7.10.2. Financial Highlights
        • 7.10.3. Product Portfolio
        • 7.10.4. SWOT Analysis
        • 7.10.5. Key Strategies and Developments
      • 7.11. Modra Pharmaceuticals
        • 7.11.1. Company Overview
        • 7.11.2. Financial Highlights
        • 7.11.3. Product Portfolio
        • 7.11.4. SWOT Analysis
        • 7.11.5. Key Strategies and Developments
      • 7.12. Pierre Fabre
        • 7.12.1. Company Overview
        • 7.12.2. Financial Highlights
        • 7.12.3. Product Portfolio
        • 7.12.4. SWOT Analysis
        • 7.12.5. Key Strategies and Developments
      • 7.13. Roche
        • 7.13.1. Company Overview
        • 7.13.2. Financial Highlights
        • 7.13.3. Product Portfolio
        • 7.13.4. SWOT Analysis
        • 7.13.5. Key Strategies and Developments
      • 7.14. Sanofi-Aventis
        • 7.14.1. Company Overview
        • 7.14.2. Financial Highlights
        • 7.14.3. Product Portfolio
        • 7.14.4. SWOT Analysis
        • 7.14.5. Key Strategies and Developments
      • 7.15. Seattle Genetics
        • 7.15.1. Company Overview
        • 7.15.2. Financial Highlights
        • 7.15.3. Product Portfolio
        • 7.15.4. SWOT Analysis
        • 7.15.5. Key Strategies and Developments
      • 7.16. Tocris Bioscience
        • 7.16.1. Company Overview
        • 7.16.2. Financial Highlights
        • 7.16.3. Product Portfolio
        • 7.16.4. SWOT Analysis
        • 7.16.5. Key Strategies and Developments
    • 8. Assumptions and Acronyms
    • 9. Research Methodology
    • 10. Contact
    • Abraxis Biosciences
    • Agensys
    • Amgen
    • Celgene
    • Eagle Pharmaceuticals
    • Endocyte
    • Genentech
    • Immunogen
    • Modra Pharmaceuticals
    • Pierre Fabre
    • Roche Holding AG Company Profile
    • Sanofi-Aventis
    • Seattle Genetics
    • Tocris Bioscience
  • settingsSettings

Related Reports

Our Clients

  • Our Clients
Inquiry Before Buying

Cancer Tubulin Inhibitors Market
  • 39241
  • Aug 2022
    • ★★★★★
      ★★★★★
    • (60)
  • US $5,999
    US $2,999
  • US $7,999
    US $3,499
  • US $12,999
    US $4,499
Buy Now
✖
Request a Sample Report
We'll get back to you as quickly as possible

Single User
$5,999
$2,999
USD / per unit
save 50%
 Multi User
$7,999
$3,499
USD / per unit
save 55%
 Corporate User
$12,999
$4,499
USD / per unit
save 65%
e-Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization No up to 10 hrs work up to 30 hrs work
Accessibility 1 User 2-5 User Unlimited
Analyst Support up to 20 hrs up to 40 hrs up to 50 hrs
Benefit Up to 20% off on next purchase Up to 25% off on next purchase Up to 30% off on next purchase
Buy Now ($ 2,999)Buy Now ($ 3,499)Buy Now ($ 4,499)
Find Help
Legal
Explore